Marker Therapeutics (MRKR) Interest Expenses (2010 - 2014)

Marker Therapeutics (MRKR) has 5 years of Interest Expenses data on file, last reported at $15425.0 in Q3 2014.

• Interest Expenses for Q3 2014 came in at $15425.0, changed N/A year-over-year; the trailing twelve-month figure through Jun 2015 was $15425.0 (down 56.26% YoY), and the FY2015 annual result was $10925.0, changed N/A from the prior year.
• Interest Expenses declined to $15425.0 in Q3 2014 per MRKR's latest filing, from $35269.0 in the prior quarter.
• Over five years, Interest Expenses peaked at $458565.0 in Q3 2010 and troughed at $15425.0 in Q3 2014.
• A 5-year average of $194780.7 and a median of $112247.5 in 2011 frame the typical range for Interest Expenses.
• The sharpest annual moves came in 2013 and 2014: Interest Expenses surged 246.22% in 2013, then plunged 89.47% in 2014.
• A 5-year view of Interest Expenses shows it stood at $446660.0 in 2010, then sank by 72.96% to $120755.0 in 2011, then fell by 16.98% to $100246.0 in 2012, then soared by 234.07% to $334888.0 in 2013, then sank by 95.39% to $15425.0 in 2014.
• Business Quant data shows MRKR's Interest Expenses at $15425.0 in Q3 2014, $35269.0 in Q1 2014, and $334888.0 in Q1 2013.